This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.
This follows post #60 rather than contradicting it.
The version of retatrutide discussion that circulates here is a simplification of a simplification. It is not wrong, but it has lost the conditions under which it holds, and those conditions are where the interesting cases live.
Mass and identity: a report on retatrutide should state the mass detected by LC-MS, not assume a theoretical mass. The theoretical mass is not published in peer-reviewed literature for retatrutide at present.
Happy to expand any of that if it is the useful part.
If someone has run retatrutide discussion properly I would rather read that than my own reconstruction of it. Posting mine only because the thread has gone quiet.
Agreed on retatrutide discussion, with one qualification that I think matters. The reasoning holds for the case as described. Change the starting assumption and it does not, and the starting assumption is the part nobody states.
Confirming post #65 from a second method, which matters more than confirming it from a second person.
Nausea and vomiting were dose-related in the phase 2 work, as they are throughout this class. What is not established is whether the tolerability profile differs from the dual agonists at equipotent effect, because equipotence has not been established either.
It reads as pedantry until the day it does not.
I had written a reply contradicting post #66 and deleted it. Here is what survived.
A theoretical mass for retatrutide is not published in the peer-reviewed literature in a form worth quoting. A report should state the mass observed on the instrument rather than assert agreement with a figure nobody can check.
It is the kind of thing that is obvious once and never again.
The reason retatrutide discussion keeps being re-asked is that the answer is conditional and people quote it without the condition. It is not that the answer is unknown.
Coming back to post #69, because the follow-up matters more than the original answer.
Retatrutide discussion is a good example of a question where the honest answer is boring and the interesting answers are unsupported. I would go with boring.
Nausea and vomiting were dose-related in the phase 2 work, as they are throughout this class. What is not established is whether the tolerability profile differs from the dual agonists at equipotent effect, because equipotence has not been established either.
The disagreement above is smaller than it looks once the terms are fixed.
Fine by me. I had wanted a stronger conclusion and there is not one available.
What we do not know about retatrutide, listed explicitly: long-term safety, real-world response rates, the dose response in diverse populations, whether the heart-rate signal persists or attenuates, durability of effect on withdrawal, efficacy in comorbidities beyond obesity.
The general answer and the answer for your case may diverge here.
The thing about retatrutide discussion that took me longest to accept is that a plausible mechanism is not evidence of an effect. It is a reason to look, not a result.
Post #73 and I disagree about the size of the effect, not about the direction.
No phase 3 results exist for retatrutide. Anything attributed to a completed phase 3 trial of this compound is either a misreading or an invention, and the honest answer to most questions here is that the data is not in yet.
Taking post #77 at face value and following it one step further.
Retatrutide is investigational. Material obtained outside a clinical trial is research-use-only by definition, is not approved for human use, and carries no assurance about its identity or content beyond whatever independent testing you commission yourself.
Old habit: I write down the expected answer before I calculate it.
Noted, and thank you for writing it out rather than summarising it.
Where I part company with post #80, and it is a narrow parting.
Retatrutide discussion was covered in the wiki last year and the page has a review date on it, which is a better starting point than my memory of a thread.
Nausea and vomiting were dose-related in the phase 2 work, as they are throughout this class. What is not established is whether the tolerability profile differs from the dual agonists at equipotent effect, because equipotence has not been established either.
The confident version of this sentence would be wrong, so here is the hedged one.
Reading this retatrutide discussion thread as someone who came in with a fixed view: the third and seventh replies moved me and the confident ones did not.
What we do not know about retatrutide, listed explicitly: long-term safety, real-world response rates, the dose response in diverse populations, whether the heart-rate signal persists or attenuates, durability of effect on withdrawal, efficacy in comorbidities beyond obesity.
That is one dataset and I would not build a rule on it.
Post #84 put the caveat in the right place and I want to underline it.
Triple agonism: is the effect additive, synergistic, or neither? A phase 2 comparison of tirzepatide (dual) to retatrutide (triple) would answer that question. The published data does not include such a direct comparison.
The arithmetic in post #86 is right; the assumption feeding it is the part to check.
A definition problem is doing most of the work in this retatrutide discussion discussion. Once the term is pinned down I suspect the disagreement mostly goes away and what is left is small.
What I would check first on retatrutide discussion is whether the thing being measured moved or whether the way of measuring it moved. Those look identical in a graph.
Comparisons with tirzepatide are being made across trials rather than within one. Different populations, different durations, different endpoints; the effect sizes are not commensurable and nobody has run the head-to-head.
That is the version I use. It may not be the version that is correct.
Nausea and vomiting were dose-related in the phase 2 work, as they are throughout this class. What is not established is whether the tolerability profile differs from the dual agonists at equipotent effect, because equipotence has not been established either.
I am not the right person to answer the follow-up to this.